GLP-1 Debate Highlights Caution Over Weight-Loss Drugs Despite Lower Prices

A debate around GLP-1 weight-loss drugs has gained attention after $BIOCON Executive Chairperson Kiran Mazumdar-Shaw cautioned against their widespread use among people who are neither diabetic nor clinically obese. Responding to Zerodha founder Nithin Kamath's observation that demand for affordable generic GLP-1 drugs in India remains weaker than expected, Mazumdar-Shaw said lifestyle changes such as diet and exercise should remain the first line of treatment, citing uncertainty over the drugs' long-term effects. Kamath noted that despite falling prices and rising obesity levels, adoption of GLP-1 medicines has been slower than anticipated in India. Experts believe factors such as conservative prescribing practices, cultural preferences, and concerns about long-term safety may be limiting demand. Industry & Economic Impact: The discussion underscores the growing opportunity in India's obesity and diabetes treatment market while highlighting that widespread adoption of GLP-1 therapies may take longer than expected. Pharmaceutical companies developing or marketing these drugs could see gradual rather than rapid growth, as doctors and patients continue to weigh long-term benefits against potential risks. From an economic perspective, increasing use of GLP-1 drugs could reshape healthcare spending, improve long-term health outcomes, and create significant opportunities for India's pharmaceutical industry. However, cautious adoption suggests that lifestyle management and preventive healthcare are likely to remain central to obesity treatment, delaying any major disruption to healthcare delivery or consumer spending patterns. Source: NDTV Profit No Recommendations